Affordable Access

The effect of HN-65021 on responses to angiotensin II in human forearm vasculature.

Authors
  • Cockcroft, J R1
  • Chowienczyk, P J
  • Brett, S E
  • Mant, T G
  • Durnin, C
  • Lynn, F
  • Stevenson, P
  • Ritter, J M
  • 1 Department of Clinical Pharmacology, UMDS St Thomas' Hospital, London, U.K.
Type
Published Article
Journal
British journal of clinical pharmacology
Publication Date
December 1995
Volume
40
Issue
6
Pages
591–593
Identifiers
PMID: 8703667
Source
Medline
License
Unknown

Abstract

We studied the effect of (2-butyl-4-chloro-1[[2'-(1H-tetrazol-5-yl) [1,1'-biphenyl]methyl]-1H-imadazole-5-carboxylic acid,-1-(ethoxycarbonyloxy) ethyl-ester (HN-65021), on angiotensin II induced vasoconstriction in forearm vasculature of eight healthy men. Placebo and HN-65021 (5, 10 and 100 mg) were administered orally. Forearm blood flow was measured by venous occlusion plethysmography during rising dose brachial artery infusions of angiotensin II (0.3-1000 pmol min-1) 2 h after dosing. HN-65021 inhibited angiotensin II, causing a shift to the right of the dose-response curve. Angiotensin II (100 pmol min-1) decreased mean blood flow in the infused arm by 63.1 +/- 3.2% when infused following placebo and by 49.9 +/- 4.3%, 50.7 +/- 3.5% and 36.4 +/- 2.8% following HN-65021 doses of 5.10 and 100 mg respectively. These results demonstrate that HN-65021 antagonises angiotensin II receptor mediated vasoconstriction in human forearm resistance vessels.

Report this publication

Statistics

Seen <100 times